Cipla Ltd (CIPL.BO)
312.40INR
5:25am EST
Rs-8.45 (-2.63%)
Rs320.85
Rs320.85
Rs323.00
Rs311.50
178,922
156,123
Rs363.00
Rs185.35
CIPL.BO
About
Overall
| Beta: | 0.38 |
| Market Cap (Mil.): | Rs257,617.30 |
| Shares Outstanding (Mil.): | 802.92 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| CIPL.BO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.67 | 1.96 | 3.76 |
| EPS (TTM): | 51.63 | -- | -- |
| ROI: | -- | 0.92 | 2.30 |
| ROE: | -- | 1.27 | 2.82 |
TABLE-India's Cipla Dec qtr net up 30 pct
(Versus the same period a year earlier, in billion rupees unless stated)
UPDATE 1-India Dr Reddy's incurs Q3 loss, cuts FY10 f'cast
* Net loss at 5.22 bln rupees vs f'cast of 1.45 bln profit
Indian shares seen up; banks in focus
MUMBAI, Jan 5 (Reuters) - Indian shares are likely to open higher on Tuesday, tracking gains in global markets which rose on optimism the global economic recovery is sustainable.
India's Cipla in drug supply talks with GSK, Teva
HONG KONG (Reuters) - Indian drug maker Cipla is in talks with drug companies including GlaxoSmithKline and Israel's Teva to supply generic drugs, its chairman said on Monday.
UPDATE 1-India's Cipla in drug supply talks with GSK, Teva
* Also confirms in negotiations with Boehringer Ingelheim
India's Cipla in drug supply talks with GSK, Teva
HONG KONG, Jan 4 (Reuters) - Indian drug maker Cipla Ltd is in talks with multinational and leading generic drug companies, including GlaxoSmithKline and Israel's Teva , to supply generic drugs, its chairman said on Monday.
Cipla, Boehringer in talks for supply pact: report
MUMBAI (Reuters) - German drugmaker Boehringer Ingelheim has started discussions with India's Cipla for a drug supply agreement, the Economic Times said, citing two unidentified persons familiar with the matter.
Cipla, Boehringer in talks for supply pact-report
MUMBAI, Dec 16 (Reuters) - German drugmaker Boehringer Ingelheim has started discussions with India's Cipla for a drug supply agreement, the Economic Times said, citing two unidentified persons familiar with the matter.
India's Cipla says gets govt demand on drug pricing
MUMBAI, Dec 7 (Reuters) - India's Cipla Ltd has received a demand notice from a government agency for 201.4 million rupees ($4.3 million) for alleged overpricing of a drug and interest costs, the drug maker said on Monday.
UPDATE 1-Japan's Takeda hires India head, to decide on entry
* Company hires industry veteran as India ops head - spox
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
